New federal board gets binding veto over risky life sciences research funding

What it does

This bill creates a new independent federal agency called the Life Sciences Research Security Board to review and approve all federal funding for high-risk life sciences research before money is awarded. The Board—composed of 9 scientists, national security experts, and biosafety specialists—has binding authority to block, approve, or impose safety conditions on research involving dangerous pathogens or gain-of-function experiments. Researchers and federal agencies must attest to whether their work is high-risk, and the Board can audit past and ongoing research to ensure compliance.

Why we flagged it

The bill's core mechanism is the creation of a binding pre-award review board for high-risk life sciences research. It is fundamentally a regulatory gatekeeping and safety-review instrument, not a deregulation or subsidy. The Board's authority is narrow but absolute: it can only approve, block, or condition funding for research meeting statutory definitions of high-risk work.

What the text implies

• The Board's definition of 'high-risk life sciences research' is expansive and includes any research the Board itself votes to add to the category by Federal Register notice, creating open-ended regulatory scope that can grow without new legislation.
• Researchers must pause work within 24 hours of identifying a change in circumstances that might make ongoing research high-risk, creating operational friction and potential liability for honest disclosure of research evolution.
• The Board retains 'final and ultimate authority' over classification disputes with agencies, potentially creating conflicts between the Board's judgment and agency scientific expertise, especially at NIH and DoD.
• Agencies must report all employee violations of attestation and certification rules to the Board and Congress quarterly, creating a new transparency mechanism but also a potential chilling effect on research proposal discussion.
• The Board can audit and review all past federally funded life sciences research conducted before the law's enactment, retroactively applying new standards to work that was lawful when conducted.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The Board creates an independent safety checkpoint for federally funded research with pandemic or bioweapon potential, reducing the risk that dangerous research proceeds without expert biosecurity review. Citizens benefit from binding oversight of gain-of-function and dual-use pathogen research, which poses catastrophic public health and national security risks. The Board's independence from agencies and political pressure, combined with mandatory disclosure and enforcement mechanisms, strengthe

Named in the bill

Life Sciences Research Security Board, Executive Director of the Board, Committee on Homeland Security and Governmental Affairs (Senate), Committee on Energy and Commerce (House), Director of the Office of Government Ethics, National Institute of Allergy and Infectious Diseases (NIAID), Department of Defense, Department of Homeland Security, Department of Energy, Office of the Director of National Intelligence, Comptroller General / GAO

Where it stands

• Mar 5, 2025 — Introduced · Congress.gov: “Introduced in House”
• Mar 5, 2025 — Referred to House Committee on Energy and Commerce and House Committee on Science, Space, and Technology · Congress.gov: “Referred to the Committee on Science, Space, and Technology, and in addition to the Committee on Energy and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

6 lobbying clients named this bill on 9 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $2,159,833 in lobbying spend. A filing names 17 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 82% of bills with at least one filing.

H. Griffith, the sponsor, reported $1,286,206 in PAC receipts in the 2026 cycle.

• Association of American Medical Colleges — $1,529,833 on 2 filings
• University of Michigan — $300,000 on 2 filings
• American Society for Microbiology — $100,000 on 2 filings
• Michigan State Univ — $90,000 on 1 filing
• Rutgers the State University of New Jersey — $80,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.